Screening for Alzheimer's disease: plasma biomarkers and what else?

Article Clinical Neurology

Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer's disease

Joshua Stevenson-Hoare et al.

Summary: Plasma biomarkers for Alzheimer's disease-related pathologies have made significant progress in recent years, with well-validated blood tests available for the detection of amyloid and tau pathology, as well as neurodegeneration and astrocytic activation. This study demonstrates that a combination of five plasma biomarkers, along with genetic variants associated with these biomarkers, can be used to accurately diagnose and predict the onset of Alzheimer's disease.

BRAIN (2023)

添加到收藏夹

Editorial Material Pharmacology & Pharmacy

Blood-Based Alzheimer's Biomarkers

[Anonymous]

CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)

添加到收藏夹

Article Clinical Neurology

Plasma biomarkers for Alzheimer's Disease in relation to neuropathology and cognitive change

Denis S. Smirnov et al.

Summary: Plasma biomarkers show promise in identifying the pathological features of Alzheimer's Disease. P-tau181 and P-tau231 are diagnostic biomarkers related to AD neuropathological change and can predict future cognitive decline. NfL can predict cognitive decline and is increased in non-AD cases. Plasma A beta 42/40 is a relatively weak predictor of amyloid pathology and may require different assay methods for improvement.

ACTA NEUROPATHOLOGICA (2022)

添加到收藏夹

Review Clinical Neurology

Blood-based biomarkers for Alzheimer's disease: towards clinical implementation

Charlotte E. Teunissen et al.

Summary: Recent research suggests that blood-based biomarkers for Alzheimer's disease may become a reality, with consistent results across different cohorts. Additionally, other blood-based biomarkers can provide information about disease progression and treatment effects.

LANCET NEUROLOGY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures

Sebastian Palmqvist et al.

Summary: Plasma P-tau, in combination with plasma phospho-tau and other biomarkers, along with clinical tests and APOE genotyping, can accurately predict the risk of Alzheimer's disease dementia, improving diagnostic prediction and facilitating recruitment for clinical trials.

NATURE MEDICINE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology